XENE — Xenon Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$60.02
+$0.02 (+0.03%)
Xenon Pharmaceuticals Inc (XENE) is a biotechnology company listed on NASDAQ. It is led by Ian C. Mortimer C.M.A., CPA, M.B.A., based in 200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8, with about 316 employees. Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Net income was -$240.6M. XENE currently screens at market cap $2.55B.
Use this XENE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the XENE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the XENE SEC filings page. Lician reads the product cache first so this HTML stays unique to Xenon Pharmaceuticals Inc even when a live quote feed is slow.
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Key Statistics
Market Cap
$2.55B
Volume
417,638
Previous Close
$60.56
Day Range
$60.26 – $61.67
EPS
-$3.01
Revenue
$0.00
Net Income
-$234.33M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
316
XENE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$234.33M | -$182.39M | -$125.37M | -$78.88M |
| EPS (Diluted) | -$3.01 | -$2.73 | -$2.06 | -$1.77 |
Total Assets
$798.14M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$142.71M
Operating Cash Flow
-$181.39M
Free Cash Flow
$0.00
Xenon Pharmaceuticals Inc Company Information
- President, CEO & Director
- Ian C. Mortimer C.M.A., CPA, M.B.A.
- Headquarters
- 200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8
- Website
- www.xenon-pharma.com
- Phone
- 604 484 3300
- IPO / Founded
- 2014-11-05
- Sector
- Healthcare
- Industry
- Biotechnology